



NATIONAL ASSOCIATION OF
SPECIALTY PHARMACY
1800 Diagonal Road, Suite 600
Alexandria, VA 22314
www.naspnet.org

March 3, 2017

Cynthia Tudor
Acting Director, Center for Medicare
Centers for Medicare & Medicaid Services
Hubert H. Humphrey Building, Room 445-G
200 Independence Avenue, SW
Washington, DC 20201

cc: Jennifer Wuggazer Lazio, F.S.A., M.A.A.A.
Director
Parts C & D Actuarial Group
Office of the Actuary
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244

BY ELECTRONIC DELIVERY

**Re: Advance Notice of Methodological Changes for Calendar Year
(201) for Medicare Advantage (MA) Capitation Rates, Part C and Part D
Payment Policies and 201 Call Letter**

Dear Dr. Tudor:

The National Association of Specialty Pharmacy (NASP) appreciates this opportunity to submit comments on the Centers for Medicare & Medicaid Services' (CMS') 2018 Call Letter. NASP is a non-profit trade organization representing a wide range of stakeholders in the specialty pharmacy industry. NASP has 104 corporate members and 1,200 individual pharmacists making it the leading unified voice of specialty pharmacy. Our members include the nation's leading independent specialty pharmacies, pharmaceutical and biotechnology manufacturers, Group Purchasing Organizations (GPOs), patient groups, wholesalers/distributors and practicing pharmacists.

Our leaders constantly refine the practice of specialty pharmacy with a single focus on the patients we serve to ensure better outcomes while reducing overall healthcare costs. With this guiding principle, NASP is the leading education resource for specialty pharmacists. The association

BOARD OF DIRECTORS

REBECCA SHANAHAN, JD
Avella Specialty Pharmacy
NASP President

MICHAEL R AGOSTINO, RPH
Hy-Vee, Inc.
NASP President Elect

SHEILA ARQUETTE, RPH
NASP Executive Director

CHRIS ARIYAN, MPH
Pfizer, Inc

DUANE BARNES, MBA, MS
Amgen

NICK CALLA, RPH
Cardinal Health

CARMINE DENARDO, RPH
ReCept Pharmacy, LP

GERALD GLEESON, MBA
Walgreens

PHIL HAGERMAN, RPH
Diplomat Pharmacy, Inc

ERIK HALSTROM, MBA
Managed Healthcare
Associates

HARRY HAYTER
Foundation Medicine, Inc.

LAWRENCE S. IRENE, RPH
Asembia Health Care

JAMES R. LANG, PHARM.D, MBA
Blue Cross Blue Shield
of Michigan

MARK MONTGOMERY
Specialty Pharmacy Executive

MICHAEL A. NAMETH, RPH, MBA
Specialty Pharmacy Executive

CYNTHIA RADFORD
Innovatix, LLC

KELLY RATLIFF, DPH
US Bioservices

GARY RICE, RPH, MS, MBA, CSP
Diplomat Specialty Pharmacy

ERNIE RICHARDSEN, RPH, MBA
Rite Aid Corporation

KYLE SKIERMONT, PHARM.D
Fairview Pharmacy Services

NUAMAN TYEYEB, PHARM.D, MBA
CareMed Pharmaceutical
Services

MARK VINEIS, MBA
Sandoz

DAVE WALKER
Specialty Pharmacy Executive

BURT ZWEIGENHAFT
NASP Past President



provides an online education center with over 30 continuing pharmacy education programs, hosts an annual meeting that offers education sessions and continuing education credits, and operates a certification program for specialty pharmacists.

NASP represents an industry that focuses on providing quality patient care first with an added emphasis on outcomes and patient choice. NASP believes that it shares these common goals with CMS and looks forward to partnering with the agency to ensure that all Medicare beneficiaries receive high quality cost effective care from their specialty pharmacy. Through this lens, NASP submits our comments below related to CMS' draft 2018 Call Letter.

I. Definition of Specialty Therapy and Specialty Pharmacy

As an initial matter, NASP resubmits the definitions of specialty therapy and specialty pharmacy. Current events continue to demonstrate the crucial role that specialty pharmacies play in the healthcare system. As new therapies continue to come to market with a greater emphasis on quality of care and outcomes, the specialty pharmacist is the caregiver that assures the physician, payer and PBM that the patient will maintain appropriate access while comforting the patient on their journey in managing their disease.

Below please find the definitions of both specialty therapy and specialty pharmacy, which serves as the foundation of NASP's 2018 Call Letter comments and overall advocacy efforts. The definitions share the significant theme of high touch patient services. For example, a specialty drug is defined by the many services provided in support of access, compliance and adherence; whereas, a specialty pharmacy is the state licensed and third party accredited entity providing those high touch patient services.

A. Definition of Specialty Therapy

Specialty drugs, or medications, are more clinically complex than most prescription medications and are used to treat patients with serious and often life threatening conditions including cancer, hepatitis C, rheumatoid arthritis, HIV/AIDS, multiple sclerosis, cystic fibrosis, organ transplantation, human growth hormone deficiencies, hemophilia and other bleeding disorders. Because of the complex clinical profile, intensive and extensive patient engagement by the specialty pharmacist is required. For example, many specialty therapies require significant patient education on both the disease and the prescribed therapy. Many specialty pharmacists have specialized areas of clinical expertise, which the prescribing physician relies upon to help explain the nature of the disease. Furthermore, this pharmacist then explains to the patient the prescribed regimen for the prescribed drug. It is through these services that the specialty pharmacist acts as an extension of the physician's office to educate the patient on his/her disease and empowers the patient to use the therapy appropriately. This education is a very important part of improving beneficiary outcomes and reducing unnecessary drug spend.

Further, the specialty therapy may be classified as such due to the way it is administered, the side effect profile, the disease or condition it is used to treat, special access conditions required by the manufacturer, payer authorization or benefit requirements, patient financial hardship, special handling, or any combination of these. Based on these characteristics, the payer, provider, specialty pharmacy and/or the manufacturer can or will identify the therapy as requiring the aforementioned specialized services. As a result, specialty prescription medications cannot be routinely dispensed at a typical retail community pharmacy because the typical retail pharmacy is not designed to provide the patient care or other support services that specialty medications require. Lastly, specialty drugs are often confused as being only a “limited distribution drugs (LDD)”. This is not the case as there are specialty drugs that are not part of a limited distribution network.

Cost should not be the only reason a therapy is classified as “specialty.” In fact, there are many low cost therapies that are classified as specialty because of the unique and labor intensive services required to assure proper utilization and maximize the clinical outcome. For example, select generic oral chemotherapy medications and certain generic immunosuppressant medications require special handling processes and a comprehensive, coordinated care approach to ensure successful therapeutic outcomes similar to those of higher cost therapies. Even though these therapies are low cost, they are still considered specialty therapies by plan sponsors. A therapies classification should be based on the services provided in support of the therapy and not just its cost.

B. Definition of Specialty Pharmacy

As a result of the growth of specialty therapies, the practice of specialty pharmacy has also evolved. The expert services that specialty pharmacies provide drive adherence and persistency, proper management of medication dosing and side effects, and ensure appropriate medication use. The specialty pharmacy’s patient-centric model is designed to provide a comprehensive and coordinated model of care for patients with chronic illnesses and complex medical conditions, achieve superior clinical and economic outcomes, and expedite patient access to care.

A specialty pharmacy is a state-licensed pharmacy that solely or largely provides medications for people with serious health conditions requiring complex therapies. These include conditions such as cancer, hepatitis C, rheumatoid arthritis, HIV/AIDS, multiple sclerosis, cystic fibrosis, organ transplantation, human growth hormone deficiencies, and hemophilia and other bleeding disorders. In addition to being state- licensed and regulated, NASP believes that specialty pharmacies should also be accredited by independent third parties. Accreditation represents a commitment to quality, safety and accountability.

Accreditation organizations help pharmacies develop their specialty pharmacy capacity and verify their capabilities to manufacturers and third-party payers. The prominent accrediting bodies are URAC®¹, the Accreditation Commission for Health Care (ACHC)², the Center for Pharmacy Practice Accreditation (CPPA)³ or the Joint Commission.⁴ Each of these organizations create standards that are designed to create a consensus around the practice of specialty pharmacy and guide the accreditation process. In general, the standards can address four primary areas of specialty pharmacy practice, which encompass the overall provision of pharmacy care for patients receiving these medications. These areas of focus include the organizational infrastructure to support the provision of specialty pharmacy care, patient access to medications via manufacturer requirements and benefits investigation, clinical management of the patient, and quality. The accreditation process further ensures that Medicare beneficiaries receive consistent quality of care.

Specialty pharmacies serve a critical role in the healthcare system because they connect patients who are severely ill with the medications that are prescribed for their conditions, provide the patient care services that are required for these medications, and support patients who are facing reimbursement challenges for these highly needed but also frequently costly medications. Specialty pharmacies do not establish the price of the specialty drug, but are a significant partner in driving the value of the drug towards a successful therapeutic outcome.

II. Comments to the 2018 Call Letter

On February 1, 2017, CMS issued its proposed changes for the Medicare Advantage (MA) and Part D Prescription Drug Programs (PDP) for 2018⁵ with an overarching strategic goal of improving the quality of care and general health status for Medicare beneficiaries.⁶ NASP shares these goals with CMS and offers the following comments on the draft 2018 Call Letter in furtherance of these objectives.

A. NASP Urges CMS to Expand Its Formulary Submission Requirements

The calendar year 2018 formulary submission window is from May 17, 2017 to June 5, 2017. During this timeframe each plan must submit a complete formulary as part of the plan's complete bid.⁷ The formulary is a list of drugs that the plan covers with further details related to tiering and cost sharing for each of the covered drugs. In turn, CMS reviews each formulary to assure compliance with its "substantially all," minimum of two drugs per class and anti-

¹ <https://www.uranet.org/accr-creditation-and-measurement/accr-creditation-programs/all-programs/specialty-pharmacy/>

² <http://www.achc.org/programs/pharmacy/pharmacy-accreditation-process>

³ <https://pharmacypracticeaccredit.org/our-programs/specialty-pharmacy-practice-accreditation-program>

⁴ http://www.jointcommission.org/accr-creditation/accr-creditation_main.aspx

⁵ See <https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Advance2018.pdf>

⁶ *Id.* at 78.

⁷ *Id.* at 134.

discrimination requirements. NASP fully supports this process as it attempts to provide all Medicare beneficiaries with access to clinically appropriate medications.

As NASP stated in previous comments to Draft Call Letters and in meetings with the agency, NASP believes, however, that this process does not go far enough to ensure access to needed medications. Just because a plan submits a formulary does not mean the Medicare beneficiary has timely and appropriate access to all therapies listed on the formulary. Rather, the beneficiary still needs to find an in-network specialty pharmacy that can fill a prescription for that specialty therapy. Not every specialty therapy is available at every specialty pharmacy.

In other words, for a specialty therapy, as defined above, accessing the specialty therapy is not as simple as using one of the many local retail chain pharmacies. Instead, the prescription must be sent to a specialty pharmacy that is in-network with both the manufacturer and the payer. As such, NASP urges CMS to require each plan sponsor to submit each specialty pharmacy or pharmacies that it has in-network for each of the formulary drugs within the oncology, immunomodulators, multiple sclerosis, HIV/AIDS, HepC and immunosuppressant classes. By doing so, CMS will know which specialty pharmacies are in-network by drug and can therefore truly determine if each Medicare beneficiary enrollee has access to each of the formulary's specialty drugs. By adopting this process, the agency will also have greater visibility into the network adequacy of each plan. This visibility will help CMS ensure that each Medicare beneficiary will truly have access to their needed specialty medications regardless of the plan he or she chooses.⁸

In turn, CMS can then provide this information on its plan finder website creating greater transparency for providers and beneficiaries when selecting a health plan as they will now know their in-network specialty pharmacy. As such, when the beneficiary researches the most appropriate plan for their needs, he or she will know which specialty pharmacy is in-network for their specialty medication. Additionally, the physician's office will also know which specialty pharmacy is in network for the drug and can immediately send the prescription to the appropriate in-network pharmacy.

By ensuring that each plan has an in-network pharmacy by specialty drug, CMS could help reduce overall health costs for the following two reasons. First, the Medicare beneficiary will always be getting the financial benefit of accessing an in-network pharmacy as compared to an out-of-network pharmacy. Second, administrative costs will be reduced as the specialty pharmacy will not have to spend time and resources transferring the prescription to an in-network specialty pharmacy. This simple administrative requirement of the sponsor will greatly improve transparency for Medicare beneficiaries while potentially reducing their out-of-pocket

⁸ The Social Security Act (SSA) Section 1860D-11(d)(2)(A) states that the "Secretary has the authority to negotiate the terms and conditions of the proposed bid submitted and other terms and conditions of a proposed plan." Since the formulary is part of the plan's complete bid, it seems to reason that the Secretary can require each plan to submit its in-network specialty pharmacy by specialty drug as part of the bid process.

costs. Similarly, NASP believes that plan sponsors should notify the agency of changes to the specialty pharmacy network in order to monitor and make sure that beneficiaries have continued access to specialty drugs throughout the plan year.

B. Access to Preferred Cost Sharing Pharmacies Should Also be Applied to Specialty Pharmacies

As mentioned above, NASP urges CMS to require plan sponsors to identify each in-network pharmacy for the oncology, immunomodulators, multiple sclerosis, HIV/AIDS, HepC and immunosuppressant classes in its formulary submission. The agency currently requires this of sponsors for retail pharmacies when it states that

“[t]he current policy has improved access to RETAIL preferred cost-sharing pharmacy (PCSPs) since it was first implemented, and we will continue to apply the same outlier thresholds that have been in place since CY 2016. Therefore, plans that provide PCSP pharmacy access within 2 miles of less than 40% of beneficiaries’ residences in urban areas, within 5 miles of less than 87% of beneficiaries’ residences in suburban areas, and within 15 miles of less than 70% of beneficiaries’ residences in rural areas will be identified as outliers in 2018 and succeeding years, unless CMS notifies sponsors of a change in the thresholds in a future Call Letter.”⁹

The agency clearly monitors beneficiary access to PCSPs in the retail channel because it saves money for the beneficiary as the PCSP is in the PBM’s network. By being in network the beneficiary’s costs are lower. By permitting PCSPs the agency is incentivizing the market to create lower cost options for beneficiaries while protecting appropriate access to the therapy in the retail channel.

If CMS requires this of the retail channel, NASP believes that the agency should similarly require this cost benefit within the specialty channel. By requiring plans to have in-network pharmacies for which their PBM does not have a financial interest for all drugs mentioned in the classes above, the agency would similarly be providing beneficiaries a lower cost option than if the beneficiary “accessed” the drug out of network. It seems to NASP that this is an easy way to stimulate market based competition for in-network access to specialty therapies.

C. The Specialty Tier is Misnamed and Disadvantages the Most Vulnerable Medicare Beneficiaries

Since the launch of the Part D program, CMS has permitted sponsors to design its exception process so that very high cost or unique drugs are not eligible for a tiering exception. Only Part D drugs with sponsor-negotiated prices that exceed an established dollar-per-month

⁹ Call Letter at 139.



threshold are eligible for specialty tier placement and therefore exempt from the tiering exception process. The current cost threshold is \$670 for calendar year 2017, which the agency proposes for 2018.¹⁰

As stated above, NASP believes that the majority of specialty drugs are so designated in part because of their costs but also in larger part because of the services required to support and maintain appropriate access to that drug. When a prescription for a specialty drug is adjudicated on the specialty tier this typically results in a significant co-insurance obligation for the Medicare beneficiary, especially in the beginning of each calendar year. The Medicare beneficiary often needs further financial assistance to pay for the drug. So, in addition to worrying about managing their disease, the beneficiary must now also worry about managing their co-insurance obligation. The specialty tier policy adds to the beneficiary's stress by shifting a dramatic portion of cost of the therapy to them. This is what our specialty pharmacists experience with each of these vulnerable patients as we work with them and their families to help bridge this stressful financial gap to help ensure timely access to the therapy.

NASP therefore respectfully requests that CMS either dramatically increase the dollar per month threshold or eliminate the tier. Relative to the overall size of the Medicare population, very few Medicare beneficiaries require a specialty tier drug, yet they absorb a significant out-of-pocket cost for utilizing this type of drug. NASP believes that this is not what Congress intended in providing an insurance benefit to its Medicare beneficiaries. The concept of insurance is to spread risk amongst a large population, not to focus costs of an unforeseen event on a select few. In fact, NASP believes that eliminating the specialty tier and spreading this specialty drug expense throughout the general Medicare population may cost as little as one dollar per month per enrollee. This is why insurance exists, to spread the risk of catastrophic events over a large population. What Medicare enrollee wouldn't pay one extra dollar per month to ensure itself against the costs of the co-insurance of a specialty drug?

Since CMS has established the specialty tier based exclusively on cost, NASP suggests that CMS change the name of the specialty tier to "high cost tier," or something similar, which is a much more accurate reflection of the criteria for inclusion. As we discussed above, there is a difference between a specialty medication and a high cost medication. By changing the name, the agency will help further create this distinction and can then further drill down on what product support services each plan sponsor is providing in support of specialty drugs, for example adherence and compliance programs, disease education materials and administrative support.

In fact, NASP urges CMS to consider requiring plan sponsors to disclose the nature and type of product support services that it or its downstream providers are providing for each of the specialty drugs. Without these services, such as adherence and compliance programs, beneficiary compliance can be inconsistent and disjointed which negatively impacts outcomes and usually increases overall cost of care. Therefore, NASP believes that the disclosure of these programs by the plan sponsors to the agency will help the agency further distinguish between just high cost and specialty drugs, reduce overall healthcare costs, and improve health


¹⁰ Id. at 144.

outcomes. Finally, the list of product support services could serve as the foundation for future quality measures within the Part D program.¹¹

III. Conclusion

NASP greatly appreciates the opportunity to comment on CMS' Draft 2018 Call Letter. NASP looks forward to continuing to work with CMS to ensure that Medicare beneficiaries have access to critical medications. Please contact me at (703) 842-0122 if you have any questions regarding our comments. Thank you for your attention to this very important matter.

Respectfully submitted,



Sheila Arquette

Executive Director, NASP

¹¹ The Social Security Act (SSA) Section 1860D-11(d)(2)(A) states that the "Secretary has the authority to negotiate the terms and conditions of the proposed bid submitted and other terms and conditions of a proposed plan." Similar to above, since the specialty tier is part of the formulary which is also part of the plan's complete bid, it seems to reason that the Secretary can require each plan to submit its product support services by specialty drug as part of the bid process.